CT ‐ P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study
Allergy · 2025
DOI: 10.1111/all.16446 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2025. Verfasst von Sarbjit S Saini und 16 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins Asthma & Allergy Center, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Celltrion Inc, Celltrion.
Abstract (Originalsprache)
Background
This study compared the therapeutic equivalence of CT‐P39 (an omalizumab biosimilar) and EU‐approved reference omalizumab (ref‐OMA) in patients with chronic spontaneous urticaria.
Methods
This double‐blind, randomized, active‐controlled Phase 3 study (NCT04426890) included two 12‐week treatment periods (TPs). In TP1, patients received CT‐P39 300 mg, ref‐OMA 300 mg, CT‐P39 150 mg, or ref‐OMA 150 mg. In TP2, patients treated with ref‐OMA 300 mg were rerandomized to CT‐P39 300 mg or ref‐OMA 300 mg; patients initially randomized to CT‐P39 300 mg continued this regimen; and patients initially randomized to CT‐P39 or ref‐OMA 150 mg received 300 mg dosing with the same drug. The primary endpoint for the assessment of therapeutic equivalence of CT‐P39 300 mg and ref‐OMA 300 mg was change from baseline in weekly itch severity score (ISS7) at week 12.
Results
In TP1, 619 patients were randomized (CT‐P39 300 mg, n = 204; ref‐OMA 300 mg, n = 205; CT‐P39 150 mg, n = 107; ref‐OMA 150 mg, n = 103). Equivalence was demonstrated between CT‐P39 300 mg and ref‐OMA 300 mg for mean change from baseline in ISS7 at week 12; confidence intervals (CIs) were within predefined equivalence margins: global analysis: treatment difference 0.77, 95% CI –0.37 to 1.90; US analysis: treatment difference 0.70, 90% CI –0.22 to 1.63. The proportion of patients experiencing ≥ 1 treatment‐related adverse event was comparable across groups. Secondary efficacy, quality of life, pharmacokinetic, safety, and immunogenicity outcomes were comparable between groups at a given dose level, with no evident impact of switching.
Conclusions
Equivalent efficacy was observed between CT‐P39 and ref‐OMA, with comparable safety also evident.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Johns Hopkins Asthma & Allergy Center, Baltimore, Maryland, USA.
- Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
- Clinical Hospital of Emergency Medical Care of Dniprovska City Council, Dnipro, Ukraine.
- Specjalistyczny NZOZ Alergologia Plus, Poznań, Poland.
- Medical Center Hera, Sofia, Bulgaria.
ORCID-Profile: Marcus Maurer, Clive Grattan
Förderung
- Celltrion Inc
- Celltrion
Zitieren
APA
Saini, S. S., Maurer, M., Dytyatkovska, Y., Springer, E., Ratkova, M., Krusheva, B., Park, C. W., Pulka, G., Chełmińska, M., Reich, A., Kim, S., Ahn, K., Kim, S., Lee, S., Ka, J., Kim, J., & Grattan, C. (2025). CT ‐ P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study. Allergy. https://doi.org/10.1111/all.16446
Vancouver
Saini SS, Maurer M, Dytyatkovska Y, Springer E, Ratkova M, Krusheva B, et al. CT ‐ P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study. Allergy. 2025. doi:10.1111/all.16446
BibTeX
@article{Saini2025,
author = {Saini, Sarbjit S and Maurer, Marcus and Dytyatkovska, Yevgeniya and Springer, Ewa and Ratkova, Maria and Krusheva, Borislava and Park, Chun Wook and Pulka, Grazyna and Chełmińska, Marta and Reich, Adam and Kim, Sunghyun and Ahn, Keumyoung and Kim, Suyoung and Lee, Sewon and Ka, Jieun and Kim, Jongho and Grattan, Clive},
title = {CT ‐ P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16446}
}
EUVIMED